Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...
6h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
For gangs, the Misuse of Drugs Act (1975) has been one of the best recruiting tools they’ve ever had. Criminalisation of a raft of illicit drugs not only provide s them with a wildly lucrative black ...
In this article, ReiThera's scientific and operational leaders discuss ReiThera’s proprietary platforms, process development ...
Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently ...
Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...
H5N1 avian flu activity is currently high, as wild birds spread the virus during their migration. Over the past 30 days, 88 ...
The post Stocks Sink Again: Market Analysis for Tuesday Nov 18th, 2025 appeared first on Stock Target Advisor.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.
Zacks Investment Research on MSN
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback